| Autor: |
Cristina de la Calle, Francisco López-Medrano, José Luis Pablos, Jaime Lora-Tamayo, Guillermo Maestro-de la Calle, Marcos Sánchez-Fernández, Mario Fernández-Ruiz, María Asunción Pérez-Jacoiste Asín, José Manuel Caro-Teller, Rocío García-García, Mercedes Catalán, Joaquín Martínez-López, Ángel Sevillano, Julia Origüen, Mar Ripoll, Rafael San Juan, Antonio Lalueza, Borja de Miguel, Octavio Carretero, Fernando Aguilar, Carlos Gómez, Estela Paz-Artal, Héctor Bueno, Carlos Lumbreras, José María Aguado |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
International Journal of Infectious Diseases, Vol 105, Iss , Pp 319-325 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1201-9712 |
| DOI: |
10.1016/j.ijid.2021.02.041 |
| Popis: |
Objectives: A subgroup of patients with SARS-CoV-2 infection was thought to have developed cytokine release syndrome and were treated with tocilizumab; however, a significant percentage of patients evolved. This study aimed to determine the usefulness of anakinra as a rescue treatment for patients with tocilizumab-refractory COVID-19 disease. Methods: A prospective cohort of patients with COVID-19 pneumonia who received anakinra as salvage therapy after failure of tocilizumab were compared (1:1) with selected controls in a historical cohort of patients treated with tocilizumab. Cases and controls were matched by age, comorbidities, pulse oximetry oxygen saturation to fraction of inspired oxygen (SpO2/FiO2) ratio at baseline, and time elapsed since the initiation of treatment with tocilizumab. The primary outcome was the improvement in clinical status measured by a 6-point ordinal scale, from baseline to day 21. Results: The study included 20 cases and 20 controls (mean age 65.3 ± 12.8 years, 65% males). No differences were found in the clinical improvement rates at 7, 14 and 21 days of follow-up. The in-hospital mortality rate for patients receiving anakinra was 55% vs. 45% in the control group (P = 0.527). Conclusions: Treatment with anakinra was not useful in improving the prognosis of patients with tocilizumab-refractory severe COVID-19. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
